Compare BWFG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BWFG | TECX |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.0M | 359.0M |
| IPO Year | N/A | 2018 |
| Metric | BWFG | TECX |
|---|---|---|
| Price | $46.95 | $19.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $53.00 | ★ $81.20 |
| AVG Volume (30 Days) | 61.0K | ★ 309.7K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 88.52 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $94,282,000.00 | N/A |
| Revenue This Year | $68.08 | N/A |
| Revenue Next Year | $13.72 | N/A |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | ★ 30.93 | N/A |
| 52 Week Low | $26.39 | $13.70 |
| 52 Week High | $51.54 | $61.07 |
| Indicator | BWFG | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 45.26 |
| Support Level | $44.95 | $20.54 |
| Resistance Level | $47.10 | $21.45 |
| Average True Range (ATR) | 1.34 | 1.19 |
| MACD | -0.47 | -0.06 |
| Stochastic Oscillator | 31.87 | 31.71 |
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.